Eli Lilly files orforglipron for type 2 diabetes in the U.S. under priority voucher pilot

Eli Lilly submitted orforglipron for type 2 diabetes in the United States during the second quarter of 2026 under the FDA's Commissioner's National Priority Voucher pilot, and a decision is possible in the fourth quarter of 2026 ^[1]. The once-daily GLP-1 tablet, sold as Foundayo, was approved by the FDA for obesity in April 2026 ^[2]. The new filing is the company's next step toward adding a type 2 diabetes indication in the U.S. ^[1][2]

Orforglipron is a small-molecule GLP-1 receptor agonist taken by mouth ^[2]. That sets it apart from semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), which are peptides. Peptides are broken down in the gut, which is why those drugs are normally injected. A small molecule survives digestion intact, so it can be given as a tablet ^[2]. Foundayo also avoids the fasting window that oral semaglutide requires. It is taken once daily at any time of day, with no food or water restrictions ^[2].

Foundayo was authorized in the United Kingdom on Aug. 10, 2026, making Britain the first country in Europe to approve the tablet ^[2]. The MHRA authorization covers adults with a body mass index of 30 or above, and adults with a BMI between 27 and 30 who have at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity ^[2]. A second indication in the U.K. covers blood sugar control in people with type 2 diabetes that is not sufficiently controlled ^[2]. Whether the U.S. filing seeks the same label wording has not been reported.

The U.K. label starts dosing at 0.8 mg and escalates through five further steps to 17.2 mg, with a minimum of one month spent at each dose level ^[2]. The most common side effects listed are nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain ^[2]. Julian Beach, the MHRA's executive director of healthcare quality and access, said the agency was pleased to be "the first regulator in Europe to authorise this tablet" ^[2].

In the U.K., the medicine is not available through the National Health Service. Lilly began supply there on Aug. 24, 2026, by private prescription only, with company-indicated private pricing of £100 to £120 per month ^[2]. NHS access would require a separate evaluation by the National Institute for Health and Care Excellence ^[2].

Why it matters for patients

An effective GLP-1 in tablet form gives people who decline injections a different route. It also removes the morning fasting and water rules that come with oral semaglutide, a practical difference for anyone whose schedule or other medications make timing difficult ^[2].

If the type 2 diabetes indication is approved in the U.S., the drug could be prescribed for blood sugar control and not only for weight management, which matters for people whose coverage or clinical need is tied to a diabetes diagnosis. The FDA's obesity approval for orforglipron is already in place ^[2].

Several practical questions are unanswered. U.S. pricing and insurance coverage for a type 2 diabetes indication have not been disclosed. It also has not been reported how much the Commissioner's National Priority Voucher pilot shortens the review, or what the FDA requires of companies in it. Orforglipron remains a prescription medicine, and the U.K. regulator lists nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain as the most common side effects ^[2].

What happens next

A U.S. decision on the type 2 diabetes filing is possible in the fourth quarter of 2026 ^[1]. In the U.K., the NICE appraisal of orforglipron remains open; NICE asked Lilly for further information after its first committee meeting and has not scheduled a second review, with an expected publication date of Nov. 18, 2026 ^[2]. Lilly's U.K. supply, which began Aug. 24, continues on a private-prescription basis while that appraisal is pending ^[2].